newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel's recently announced agreement with Searchlight Pharma will provide up to $11